1. Introduction {#sec1}
===============

The Zhenwu decoction (ZWD), one of the classic prescriptions for the treatment of Yang deficiency, was recorded in the "Treatise on Febrile Diseases" by Zhang Zhongjing. It is composed of Aconiti Lateralis Radix Praeparata (the lateral radix of *Aconitum carmichaelii* Debx.), Zingiberis (rhizome of *Zingiber officinale* Rosc.), Atractylodis Macrocephalae Rhizoma (radix of *Atractylodes macrocephala* Koidz.), Paeoniae Radix Alba (radix of *Paeonia lactiflora* Pall.), and Poria (sclerotium of *Poria cocos* (Schw.) Wolf.), and modern researches have shown that ZWD has therapeutic effects on nephrotic syndrome \[[@B1]\], Parkinson\'s disease \[[@B2]\], and chronic heart failure \[[@B3]\]. Clinically, ZWD is often used in combination with other drugs \[[@B4]\]; however, this combination may be resulting in various herb-drug interactions (HDIs).

HDIs have recently attracted wide attention, and they will lead to changes of plasma drug concentration and further affect efficacy \[[@B5]\]. Metabolic interaction is particularly important in the HDI triggers, it is becoming the main pathway for clinical HDIs, accounting for approximately 40% \[[@B6]\], and cytochrome P450 (CYP450) oxidase plays a pivotal role in metabolic interactions \[[@B7]\]. The CYP450 enzyme is the most critical metabolic enzyme system involved in the biological transformation of exogenous and endogenous substances \[[@B8]\]. The vital enzymes of the CYP superfamily are CYP1, CYP2, and CYP3, while CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 participated in 90% of clinical drug metabolism \[[@B9]\]. In rats, their orthologs are CYP1A2, CYP2B1, CYP2C7, CYP2C6, CYP2C11, CYP2D2, and CYP3A1, respectively \[[@B10]--[@B14]\].

So, with the growing demand for the safety assessment of clinical drugs, this presentation was focused on simultaneously elucidating the effects of ZWD on the activities and mRNA expressions of seven CYP450 isoenzymes in rats based on a validated UPLC-MS/MS method \[[@B5]\] and real-time quantitative reverse-transcription polymerase chain reaction (RT-qPCR) in order to promote the scientific and rational clinical use of ZWD.

2. Materials and Methods {#sec2}
========================

2.1. Materials and Instruments {#sec2.1}
------------------------------

Higenamine (No. Q-078-150731) was purchased from Beijing Zhongke Quality Control Biotechnology, Inc. (Beijing, China). Paeoniflorin (No. 110736201539) and atractylenolide III (No. 73030-71-4) were obtained from the National Institutes for Food and Drug Control (Beijing, China). 6-Gingerol (No. MUST-17120205) was purchased from Chengdu Man Site Pharmaceutical Co., Ltd. (Chengdu, China). Dehydrotumulosic acid was purchased from Chengdu Chroma-Biotechnology Co., Ltd. (Chengdu, China). Probe drugs used include phenacetin, bupropion, diclofenac, amodiaquine, omeprazole, dextromethorphan, and midazolam (Nos. 100095-201205, 100671-200301, 100334-200302, 101217-201401, 100367-201305, 100201-201003, and 171250-202002, respectively). The standard materials were supplied by the Chinese Food and Drug Administration Research Institute (Beijing, China). Glibenclamide (internal standard, no. 171250) was purchased from Yuanye Biotechnology Co., Ltd. (Shanghai, China). The purity of the standards was higher than 98%. The following materials were also acquired: TRIzol Reagent (Invitrogen, Carlsbad, CA), Verso cDNA Synthesis Kit (Thermo Fisher Scientific, MA, USA), SYBR Green PCR Kit (Qiagen, Hilden, Germany), PCR primer (Moore Biotech, Hefei, China), and DEPC water (General Biotech, Shanghai, China).

The following instruments were used: Agilent 1290 Infinity (Agilent Technologies Inc., California, USA); AB SCIEX 4500 triple-quadrupole mass spectrometer (AB SCIEX, USA); real-time quantitative PCR (Applied Biosystems, CA, USA); Acquity CSH C~18~ Column (2.1 × 100 mm, 1.7 *μ*m, Waters Corp., Mass., USA); and Millipore Milli-Q purification system (Millipore, Bedford, USA).

2.2. Preparation for ZWD Extract and Probe Cocktail {#sec2.2}
---------------------------------------------------

The dried raw herbs of ZWD were purchased from Anhui Puren Chinese Herbal Medicine Co., Ltd. (Anhui, China); *Zingiber officinale* Roscoe was homemade (fresh Anhui-origin ginger, washed, and sliced). The extraction process was as follows: *Aconitum carmichaeli* Debx : *Poria cocos* (Schw.) Wolf : *Zingiber officinale* Roscoe : *Paeonia lactiflora* Pall : *Atractylodes macrocephala* Koidz (nos. 160401, 160506, 160521, and 160613, respectively) at the proportion of 9 : 9 : 9 : 9 : 6, soaked in 10 times distilled water for 30 min and then boiled for 1.5 h, filtered, and the residue boiled with 8 times water for 1 h again. The two filtrates were mixed and concentrated to 2.1 g/mL and stored at 4°C.

The proper amount of seven probe substrates were dissolved in a certain amount (about 1/3 to 1/2 of the total volume of normal saline (NS)) of NS and anhydrous ethanol (0.5 mL). Ultrasonically stirred until homogeneous, Tween 80 was slowly dropped into the solution until it was clear and transparent. Finally, the volume with NS was determined. Notably, the solution was prepared when we needed it, and the dose of mixed probe substrates was 1 mL/kg.

2.3. Characterization of ZWD Extract by HPLC {#sec2.3}
--------------------------------------------

High-performance liquid chromatography (HPLC) was performed to support the stability and quality of the ZWD extract. The following chromatographic conditions were used: a Shimadzu LC-15C UV HPLC system with a C~18~ column (4.6 mm × 250 mm, 5 *μ*m), a column temperature of 30°C, a flow rate of 1 mL·min^−1^, a wavelength of 230 nm, and 0.05% phosphoric acid aqueous solution (A)-acetonitrile (B) gradient elution described as follows: 0-10 min, 91%-88% (A); 10-20 min, 88%-85% (A); 20-33 min, 85%-65% (A); 33-38 min, 65%-60% (A); 38-48 min, 60%-52% (A); 48-58 min, 52%-57% (A); and 58-62 min, 57%-91% (A).

2.4. Animal Treatment {#sec2.4}
---------------------

All rats were kept at a room temperature of 20 ± 2°C with a 12 h light/dark cycle and 50 ± 5% relative humidity for one week. The use of animals reported here have been approved by the Institutional Animal Care and Use Committee of Anhui Medical University (Animal Medical Ethics Committee of Anhui Medical University LLSC20160336), and the experimental procedures were conducted in accordance with the Guidelines for Proper Conduct of Animal Experiments. 48 male Sprague-Dawley (SD) rats (240\~280 g) were randomly divided into the NS group and the ZWD low- (2.1875 g/kg), medium- (4.375 g/kg), and high- (8.75 g/kg) dose groups (12 per group) \[[@B15]\]. After one week of adaptation under controlled temperature and humidity conditions, rats were given corresponding doses of ZWD or NS intragastrically once daily for 28 consecutive days. They were fasted, but water was provided ad libitum before the experiment.

2.5. Collection of Plasma and Liver Tissue Samples {#sec2.5}
--------------------------------------------------

On the 29th day, half of the 48 rats received a cocktail substrate solution through the tail vein at a dose of 1 mL/kg, and plasma samples were obtained following the established procedures \[[@B5]\]. Meanwhile, after the last administration of another 24 rats for 30 min, blood was taken from the abdominal aorta and the liver was rapidly separated. All samples were stored at -80°C for analysis.

2.6. Total RNA Isolation and cDNA Synthesis {#sec2.6}
-------------------------------------------

Based on the manufacturer\'s protocol, total RNA was isolated from 50 mg liver samples using the TRIzol Reagent. Then, the RNA concentration was determined and the absorbance ratio (*A*~260~/*A*~280~) was in the range of 1.8-2.0, indicating the excellent quality of RNA \[[@B16]\]. The RNA pellet was stored at -80°C. According to the RevertAid First Strand cDNA Kit, total RNA (2 *μ*L) was reversely transcribed into cDNA at 42°C for 60 min, 70°C for 5 min, and 4°C for 5 min. Reverse-transcription products were stored at -80°C until analysis.

2.7. RT-qPCR Analysis {#sec2.7}
---------------------

*β*-Actin as the housekeeping gene was selected. RT-qPCR was performed as follows: predenaturation at 95°C for 10 min, 95°C for 15 s, and 60°C for 60 s (40 cycles).

The forward and reverse primer sequences are listed in [Table 1](#tab1){ref-type="table"}.

2.8. Statistical Analysis {#sec2.8}
-------------------------

The main pharmacokinetic parameters were calculated by noncompartmental analysis using the DAS 2.0 software, including area under the curve (AUC), half-life time (*T*~1/2~), clearance (CL), and volume (*V*). mRNA expressions were performed by 2^−ΔΔCT^ calculation. Results are expressed as mean ± standard deviation ($\overline{x} \pm \text{SD}$). The Kruskal-Wallis test, one-way of analysis of variance (ANOVA), and the least-significant difference (LSD) test were used for statistical parameter analysis. *P* \< 0.05 was regarded as statistically significant.

3. Results {#sec3}
==========

3.1. Characterization of ZWD Extract by HPLC {#sec3.1}
--------------------------------------------

According to HPLC analysis, five compounds in ZWD extracts were identified as shown in [Figure 1](#fig1){ref-type="fig"}: higenamine (peak 1), paeoniflorin (peak 2), atractylenolide III (peak 3), 6-gingerol (peak 4), and dehydrotumulosic acid (peak 5), which provided evidence for the quality control of ZWD.

3.2. Validation of "Cocktail" Method {#sec3.2}
------------------------------------

### 3.2.1. Specificity and Linear Ranges {#sec3.2.1}

The specificity results ([Figure 2](#fig2){ref-type="fig"}) indicated that endogenous substances did not substantially interfere with the retention time of probe drugs and internal standard (IS) in blank plasma. The linear ranges of the seven probe substrates were 2-1400, 2.25-600, 30-9000, 0.6-100, 2-2000, 0.8-400, and 6-1800 (ng/mL), and the correction coefficients (*r*) were 0.9986, 0.9980, 0.9965, 0.9984, 0.9967, 09977, and 0.9996, respectively.

### 3.2.2. Precision and Accuracy {#sec3.2.2}

Interday precision and intraday precision of the method were assessed by detecting the low limit of qualification (LLOQ) and the low-, medium-, and high-quantification concentrations (LQC, MQC, and HQC) of plasma samples. Relative standard deviation (RSD) values of the precision do not exceed ±15% (Tables [2](#tab2){ref-type="table"} and [3](#tab3){ref-type="table"}).

### 3.2.3. Matrix Effect {#sec3.2.3}

By comparing the different results of analytes added into the blank sample and ultrapure water, the matrix effect was determined at LQC, MQC, and HQC concentrations. The RSD values in [Table 4](#tab4){ref-type="table"} were less than 4%, indicating that the matrix effect of plasma is negligible for quantitative analysis of all samples.

### 3.2.4. Stability {#sec3.2.4}

The stability of all probe drugs was evaluated by LQC and HQC samples under different experimental conditions, including short-term stability (4 h at room temperature (25°C), 8 h in the automatic sampler, and three freeze and thaw cycles, respectively) and long-term stability (7 d at -80°C). Results showed that the probe substrates tested were within the recommended limits, RSD \< 10% ([Table 5](#tab5){ref-type="table"}).

3.3. Effect of ZWD on Rat CYP1A2, CYP2B1, CYP2C7, and CYP2D2 Activities {#sec3.3}
-----------------------------------------------------------------------

The CYP1A2, CYP2B1, CYP2C7, and CYP2D2 activities were investigated by analyzing the pharmacokinetic parameters of phenacetin, bupropion, amodiaquine, and dextromethorphan, respectively. [Table 6](#tab6){ref-type="table"} and [Figure 3](#fig3){ref-type="fig"} present the main pharmacokinetic parameters and mean plasma concentration-time curves in different groups. Compared with the NS group, none of the differences measured were significant in ZWD groups (*P* \> 0.05), except for *T*~1/2~ changes of bupropion, amodiaquine, and dextromethorphan (*P* \< 0.05).

3.4. Effect of ZWD on Rat CYP2C6 {#sec3.4}
--------------------------------

To describe changes in CYP2C6 activity, [Table 7](#tab7){ref-type="table"} and [Figure 3](#fig3){ref-type="fig"} present the pharmacokinetic profiles and mean plasma concentration-time curves of diclofenac. The results indicated that compared with the NS group, ZWD in medium and high dose groups significantly reduced AUC~0−*t*~ and AUC~0−∞~ (*P* \< 0.05) in a dose-dependent manner, which was consistent with the CL and *V* values (*P* \< 0.05), while no changes were observed between the ZWD-L and NS groups.

3.5. Effect of ZWD on Rat CYP2C11 {#sec3.5}
---------------------------------

Omeprazole is a specific probe substrate for rat CYP2C11. The corresponding pharmacokinetic profiles and the mean plasma concentration-time curves are presented in [Table 8](#tab8){ref-type="table"} and [Figure 3](#fig3){ref-type="fig"}, respectively. Plasma omeprazole AUC~0−*t*~ and AUC~0−∞~ were significantly reduced in a dose-dependent manner (*P* \< 0.05), and the CL value was significantly increased (*P* \< 0.05), which means that drug plasma concentration was decreased and drug metabolism was accelerated. Interestingly, the CL value was the lowest in the ZWD-M group, consistent with *T*~1/2~. Accordingly, ZWD affects the drug metabolism mediated by CYP2C11.

3.6. Effect of ZWD on Rat CYP3A1 {#sec3.6}
--------------------------------

In rats, midazolam was metabolized by CYP3A1, as shown in [Table 9](#tab9){ref-type="table"} and [Figure 3](#fig3){ref-type="fig"}. After oral administration, AUC~0−*t*~ and AUC~0−∞~ decreased and CL increased as the dose increased (*P* \< 0.05); notably, *T*~1/2~ was also reduced significantly (*P* \< 0.05) and *V* was approximately constant. Changes in pharmacokinetic parameters of midazolam in rats suggested that CYP2A1 enzyme activity was induced, leading to an acceleration of the metabolism as well as a reduction of the plasma drug concentration.

3.7. Effect of ZWD on the mRNA Expression of Seven CYPs {#sec3.7}
-------------------------------------------------------

As shown in [Figure 4](#fig4){ref-type="fig"}, compared with the NS group, the mRNA expressions of CYP2C6 and CYP3A1 only increased significantly to 2.08- and 2.50-fold in the ZWD-H dose group, respectively, while no significant difference was observed in the ZWD-L and ZWD-M dose groups. Moreover, CYP2C11 mRNA expression levels were significantly increased to 2.00-, 3.33-, and 5.41-fold in ZWD-L, ZWD-M, and ZWD-H dose groups, respectively. Being in line with the enzyme activity results, the mRNA expressions of CYP1A2, CYP2B1, CYP2C7, and CYP2D2 in the ZWD group were not significantly different from those in the NS group.

4. Discussion {#sec4}
=============

Drug metabolism-induced interactions account for about half of HDIs, and CYP450 enzymes dominate in metabolism. At a basic level, a comprehensive assessment of the effects of ZWD on CYP450 enzymes is therefore critical for predicting HDIs during integrative medicine practice.

4.1. Selection of Rat Gender and ZWD Dose {#sec4.1}
-----------------------------------------

CYP450 enzyme activity is influenced by species, gender, age, environment, medication, and pathological condition \[[@B17]\]. Similar to humans, since the CYP3A activity in male rats is 5 to 10 times higher than that in female rats, male rats were selected as experimental subjects \[[@B18], [@B19]\]. At the same time, this method is possible to elucidate different factors that affect the efficacy of ZWD.

For the dosage of ZWD, the *Formulaology* textbook of the National TCM Industry, "Ancient Classics List (First Batch)" and literature \[[@B20], [@B21]\] were referred to. According to the previous experimental results, the low, medium, and high doses of ZWD were 2.1875, 4.375, and 8.75 g/kg, respectively.

4.2. Explaination of ZWD Effects on CYP1A2, CYP2B1, CYP2C7, and CYP2D2 {#sec4.2}
----------------------------------------------------------------------

As mentioned in the literature, 82 volatile components were isolated by GC-MS, and five constituents of ZWD were qualified by HPLC \[[@B22], [@B23]\]. In these components, total glucoside of paeony has inductive effects on CYP1A2 and CYP2C9 enzyme activities \[[@B21]\]; ginger extract could inhibit the CYP2C19 and CYP1A2 enzyme activities \[[@B24], [@B25]\]; and Aconiti Lateralis Radix Praeparata has effects on various CYP450 enzyme activities, such as CYP3A, CYP2D, and CYP1A2 \[[@B26]\]. Interestingly, our study demonstrated that ZWD has no effect on CYP1A2, CYP2B1, CYP2C7, and CYP2D2. Basically, similar to the compatibility mechanism of the Siwu decoction, we hypothesized that due to the different effects of the ZWD components on metabolic enzymes, the interaction between them makes the integrated effects inconsistent with the individual contribution \[[@B27]\]. The results imply that the clinical use of ZWD is better than a single herb, showing the superior compatibility of Chinese medicine formulas.

4.3. Potential Mechanism of ZWD Effects on CYP2C6, CYP2C11, and CYP3A1 {#sec4.3}
----------------------------------------------------------------------

*In vivo*, CYP3A accounts for about 40% of the total liver P450 enzymes and mediates 50-60% clinical drug metabolism such as erythromycin, nimodipine, and lidocaine \[[@B28]\]. CYP2C occupies about 20% of the total P450 enzymes and mediates the hydroxylation metabolism reaction of losartan, toluene sulfonamide, and other drugs \[[@B29], [@B30]\]. Studies have shown that *Poria cocos* aqueous extract can significantly increase the CYP2C6, CYP2B1, and CYP3A1 activities and upregulate their mRNA expressions \[[@B5]\]. What\'s more, both *Poria cocos* and Aconiti Lateralis Radix can induce pregnane X receptor (PXR) activation and further mediate the transcription and expression of CYP3A4 \[[@B31], [@B32]\]. However, whether they induce CYP3A1 activity by activating PXR and showing synergy is unclear. Additional identification is needed. In addition, based on the above studies, the drug\'s regulation of enzyme activities at a stage independent of transcription, translation, and posttranslational protein modification may explain why high-dose ZWD induced CYP2C6 and CYP3A1 activities but upregulated mRNA expression. Taken together, the core finding of this experiment is that dose adjustment and HDI risk should be taken into consideration when ZWD is used with drugs metabolized by CYP2C6, CYP2C11, and CYP3A1. Meanwhile, *V* of diclofenac, omeprazole, and midazolam exceeded the total fluid volume, indicating that they are easily ingested into tissues. The concentration of drug in tissues, therefore, also needs to be monitored clinically in real time. Notably, *T*~1/2~ of midazolam was significantly decreased, CL was consistent with it, *V* is constant, and the metabolic process of midazolam conforms to the nonlinear pharmacokinetic model.

5. Conclusion {#sec5}
=============

In summary, this dissertation was undertaken to evaluate the effects of ZWD on the activities and mRNA expressions of seven CYP450 enzymes by using a cocktail method. The method has proven to be sensitive, efficient, and reliable. Pharmacokinetic profile analysis shows that when ZWD is coadministrated with drugs metabolized by CYP2C6, CYP2C11, and CYP3A1, not only should the potential herb-drug interactions (HDIs) be observed but the dosage adjustment and tissue drug concentration should also be considered. Furthermore, the above approach can be applied to study the importance of gender, age, and disease factors to HDI prediction.
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![Identification of five components in ZWD by HPLC (peak 1: higenamine; peak 2: paeoniflorin; peak 3: atractylenolide III; peak 4: 6-gingerol; peak 5: dehydrotumulosic acid).](BMRI2020-4816209.001){#fig1}

![UPLC-MS/MS-specific chromatograms of seven probes and glibenclamide in rat plasma: (a) blank plasma; (b) probe substrates and glibenclamide (IS); (c) blank plasma spiked with phenacetin, bupropion, diclofenac, amodiaquine, omeprazole, dextromethorphan, midazolam, and IS (1-8); (d) plasma probe substrates and IS after receiving cocktail substrate solution through tail vein injection.](BMRI2020-4816209.002){#fig2}

![Mean concentration-time curves of seven probe substrates in rat plasma (ng/mL): (a) phenacetin, (b) bupropion, (c) diclofenac, (d) amodiaquine, (e) omeprazole, (f) dextromethorphan, and (g) midazolam.](BMRI2020-4816209.003){#fig3}

![Effects of ZWD on fold changes of seven CYP450 isoenzyme mRNAs in rat liver compared with NS, ^\#^*P* \< 0.05 and ^\#\#^*P* \< 0.01.](BMRI2020-4816209.004){#fig4}

###### 

The primer for the enzymes and reference genes of rat.

  CYP450      Forward primer            Reverse primer
  ----------- ------------------------- -----------------------------
  CYP1A2      CATCTTTGGAGCTGGATTTG      CCATTCAGGAGGTGTCC
  CYP2B1      AACCCTTGATGACCGCAGTAAA    TGTGGTACTCCAATAGGGACAAGATC
  CYP2C6      TCAGCAGGAAAACGGATGTG      AATCGTGGTCAGGAATAAAAATAACTC
  CYP2C7      TGTGAAGAACATCAGCCAATCCT   CACGGTCCTCAATGTTCCTTTT
  CYP2C11     GGAGGAACTGAGGAAGAGCA      AATGGAGCATATCACATTGCAG
  CYP2D2      GAAGGAGAGCTTTGGAGAGGA     AGAATTGGGATTGCGTTCAG
  CYP3A1      TGCCAATCACGGACACAGA       ATCTCTTCCACTCCTCATCCTTAG
  *β*-Actin   GCCCAGAGCAAGACAGGTAT      GGCCATCTCCTGCTCGAAGT

###### 

Accuracy of seven probe substrates in rat plasma (*n* = 5).

  Probe substrates   Mark concentration (ng/mL)   Accuracy, mean ± SD (ng/mL)   RSD (%)
  ------------------ ---------------------------- ----------------------------- ---------
  Phenacetin         2                            102.5 ± 7.79                  7.59
  4                  97.79 ± 5.19                 5.31                          
  53                 105.8 ± 5.05                 4.77                          
  1050               107.1 ± 2.27                 2.12                          
                                                                                
  Bupropion          2.25                         111.9 ± 8.38                  7.49
  4.5                104.3 ± 5.89                 5.65                          
  35                 103.4 ± 2.76                 2.67                          
  450                110.8 ± 3.48                 3.14                          
                                                                                
  Diclofenac         30                           96.44 ± 8.85                  9.17
  60                 99.54 ± 4.12                 4.14                          
  520                108.1 ± 6.25                 5.78                          
  6750               96.09 ± 4.42                 4.60                          
                                                                                
  Amodiaquine        0.6                          97.38 ± 10.9                  11.2
  1.2                102.9 ± 8.42                 8.18                          
  10                 97.22 ± 6.40                 6.58                          
  75                 103.1 ± 4.99                 4.84                          
                                                                                
  Omeprazole         2                            91.80 ± 7.01                  7.63
  4                  104.3 ± 6.63                 6.36                          
  63.5               102.0 ± 5.36                 5.25                          
  1500               103.0 ± 4.95                 4.80                          
                                                                                
  Dextromethorphan   0.8                          106.1 ± 8.04                  7.58
  1.6                100.9 ± 5.81                 5.76                          
  17.9               106.5 ± 4.41                 4.14                          
  300                98.17 ± 2.04                 2.08                          
                                                                                
  Midazolam          6                            94.37 ± 7.13                  7.56
  12                 103.8 ± 6.44                 6.20                          
  104                103.3 ± 4.18                 4.04                          
  1350               98.52 ± 2.11                 2.14                          

###### 

Precision of seven probe substrates in rat plasma (*n* = 5).

  Probe substrates   Added (ng/mL)   Interday       Intraday                       
  ------------------ --------------- -------------- --------------- -------------- ------
  Phenacetin         2               2.05 ± 0.16    7.59            2.07±0.13      6.49
  4                  4.20 ± 0.22     5.14           4.28±0.29       6.84           
  53                 58.24 ± 2.21    3.79           55.91 ± 2.35    4.20           
  1050               1125 ± 23.9     2.12           1086 ± 20.8     1.91           
                                                                                   
  Bupropion          2.25            2.52 ± 0.19    7.49            2.47 ± 0.18    7.08
  4.5                4.70 ± 0.27     5.65           4.69 ± 0.24     5.15           
  35                 37.76 ± 0.72    1.90           37.09 ± 2.19    5.89           
  450                447.6 ± 14.0    3.14           458.02 ± 6.38   1.39           
                                                                                   
  Diclofenac         30              28.71 ± 1.15   4.00            27.96 ± 2.03   7.24
  60                 55.47 ± 1.47    2.64           61.63 ± 2.63    4.28           
  520                457.9 ± 13.4    2.93           475.1 ± 31.4    6.48           
  6750               6091 ± 311.4    5.11           6381 ± 229.5    3.58           
                                                                                   
  Amodiaquine        0.6             0.58 ± 0.07    11.8            0.61 ± 0.07    11.2
  1.2                1.24 ± 0.10     8.18           1.28 ± 0.09     7.15           
  10                 9.72 ± 0.64     6.58           10.35 ± 0.66    6.36           
  75                 77.35 ± 3.75    4.84           74.53 ± 3.25    4.35           
                                                                                   
  Omeprazole         2               1.84 ± 0.14    7.63            1.90 ± 0.17    8.77
  4                  4.17 ± 0.27     6.36           4.16 ± 0.32     7.72           
  63.5               64.54 ± 3.39    5.25           63.46 ± 3.04    4.79           
  1500               1545 ± 74.2     4.8            1533 ± 62.5     4.07           
                                                                                   
  Dextromethorphan   0.8             0.87 ± 0.05    5.38            0.86 ± 0.05    6.03
  1.6                1.64 ± 0.12     7.09           1.71 ± 0.11     6.65           
  17.9               18.64 ± 0.93    5.00           19.34 ± 1.01    5.25           
  300                312.3 ± 6.63    2.12           314.2 ± 8.82    2.80           
                                                                                   
  Midazolam          6               5.66 ± 0.43    7.56            5.82 ± 0.40    6.94
  12                 12.46 ± 0.77    6.20           12.33 ± 0.76    6.18           
  104                107.4 ± 4.34    4.04           107.2 ± 5.69    5.29           
  1350               1330 ± 28.4     4.14           1382 ± 53.32    3.70           

###### 

Matrix effect of seven probe substrates in rat plasma (*n* = 6).

  Mark concentration (ng/mL)   Compounds      Matrix effect (%)   RSD (%)
  ---------------------------- -------------- ------------------- ---------
  LQC                          Phenacetin     96.04 ± 3.49        3.63
  Bupropion                    95.50 ± 2.02   2.12                
  Diclofenac                   96.97 ± 3.24   3.35                
  Amodiaquine                  95.36 ± 3.22   3.38                
  Omeprazole                   96.35 ± 3.41   3.54                
  Dextromethorphan             96.59 ± 2.08   2.15                
  Midazolam                    95.78 ± 3.14   3.28                
                                                                  
  MQC                          Phenacetin     97.59 ± 2.30        2.35
  Bupropion                    98.66 ± 1.74   1.77                
  Diclofenac                   98.09 ± 2.45   2.49                
  Amodiaquine                  95.80 ± 3.20   3.34                
  Omeprazole                   96.68 ± 1.09   1.12                
  Dextromethorphan             97.90 ± 1.58   1.61                
  Midazolam                    95.81 ± 3.18   3.32                
                                                                  
  HQC                          Phenacetin     94.79 ± 2.58        2.72
  Bupropion                    97.21 ± 1.38   1.42                
  Diclofenac                   93.51 ± 2.07   2.22                
  Amodiaquine                  92.87 ± 3.48   3.75                
  Omeprazole                   96.00 ± 1.83   1.91                
  Dextromethorphan             96.15 ± 1.19   1.23                
  Midazolam                    97.10 ± 2.57   2.65                

###### 

Stability of seven probe substrates in rat plasma (*n* = 5).

  QC                 Probe substrates   Stability (mean ± SD)                                 
  ------------------ ------------------ ----------------------- -------------- -------------- -------------
  LQC                Phenacetin         4.12 ± 0.20             4.10 ± 0.07    4.12 ± 0.12    4.26 ± 0.15
  Bupropion          4.72 ± 0.31        4.77 ± 0.26             4.79 ± 0.29    4.76 ± 0.28    
  Diclofenac         59.31 ± 2.72       59.16 ± 1.91            55.17 ± 3.72   63.06 ± 3.52   
  Amodiaquine        1.24 ± 0.09        1.27 ± 0.10             1.25 ± 0.12    1.27 ± 0.08    
  Omeprazole         4.11 ± 0.34        4.24 ± 0.29             4.07 ± 0.27    4.05 ± 0.38    
  Dextromethorphan   1.74 ± 0.09        1.67 ± 0.15             1.65 ± 0.12    1.66 ± 0.14    
  Midazolam          12.17 ± 0.88       12.20 ± 0.75            12.34 ± 0.94   11.85 ± 0.91   
                                                                                              
  HQC                Phenacetin         1103 ± 29.9             1058 ± 12.9    1130 ± 14.4    1127 ± 15.7
  Bupropion          469.9 ± 14.9       461.7 ± 19.7            465.8 ± 10.9   475.1 ± 11.9   
  Diclofenac         7611 ± 170.5       6673 ± 154.8            7061 ± 357.7   7072 ± 170.0   
  Amodiaquine        75.02 ± 2.03       76.38 ± 2.35            81.19 ± 1.72   79.96 ± 2.97   
  Omeprazole         1516 ± 70.0        1538 ± 77.4             1540 ± 59.3    1540 ± 76.4    
  Dextromethorphan   297.9 ± 7.76       314.6 ± 16.0            320.7 ± 12.8   319.0 ± 11.9   
  Midazolam          1310 ± 40.4        1413 ± 48.5             1339 ± 27.2    1370 ± 40.9    

###### 

Pharmacokinetic parameters of four probe substrates in rat plasma ($\overline{x} \pm \text{SD}$, *n* = 6).

                        Parameter               NS                   ZWD-L                ZWD-M           ZWD-H
  --------------------- ----------------------- -------------------- -------------------- --------------- --------------
  Phenacetin            AUC~0−*t*~ (mg/L·min)   9.48 ± 0.57          10.49 ± 3.85         10.69 ± 2.48    10.11 ± 1.26
  AUC~0−∞~ (mg/L·min)   9.83 ± 0.77             10.59 ± 3.86         10.85 ± 2.47         11.25 ± 1.77    
  *T* ~1/2~  (min)      32.31 ± 12.8            24.03 ± 4.26         22.53 ± 7.60         49.92 ± 15.4    
  CL (L/min/kg)         2.04 ± 0.16             2.06 ± 0.58          1.93 ± 0.44          1.82 ± 0.28     
  *V* (L/kg)            93.76 ± 30.7            72.92 ± 26.4         75.67 ± 21.3         110.3 ± 18.2    
                                                                                                          
  Bupropion             AUC~0−*t*~ (mg/L·min)   11.10 ± 1.32         12.53 ± 3.25         13.38 ± 0.69    12.04 ± 1.03
  AUC~0−∞~ (mg/L·min)   13.03 ± 4.15            15.90 ± 7.27         15.76 ± 1.73         13.67 ± 1.90    
  *T* ~1/2~  (min)      78.27 ± 8.24            64.88 ± 13.8         55.69 ± 7.74^\#\#^   71.34 ± 18.2    
  CL (L/min/kg)         1.63 ± 0.37             1.48 ± 0.65          1.28 ± 0.13          1.49 ± 0.23     
  *V* (L/kg)            485.2 ± 110.2           388.1 ± 248.8        320.2 ± 134.3        351.2 ± 43.9    
                                                                                                          
  Amodiaquine           AUC~0−*t*~ (mg/L·min)   3.76 ± 0.54          2.69 ± 0.59          3.79 ± 0.50     4.68 ± 1.74
  AUC~0−∞~ (mg/L·min)   8.92 ± 0.75             4.99 ± 3.39          5.96 ± 1.36          13.55 ± 8.45    
  *T* ~1/2~  (min)      236.4 ± 50.6            169.7 ± 118.9        126.9 ± 25.2^\#^     245.2 ± 98.2    
  CL (L/min/kg)         2.26 ± 0.20             5.28 ± 2.56          3.49 ± 0.69          2.50 ± 2.13     
  *V* (L/kg)            2072 ± 385.5            2291 ± 488.9         1618 ± 443.7         1763 ± 596.4    
                                                                                                          
  Dextromethorphan      AUC~0−*t*~ (mg/L·min)   11.28 ± 1.71         10.08 ± 2.73         11.87 ± 1.37    11.37 ± 1.47
  AUC~0−∞~ (mg/L·min)   13.59 ± 3.58            10.60 ± 2.84         12.24 ± 1.26         14.71 ± 4.04    
  *T* ~1/2~  (min)      79.09 ± 15.67           46.69 ± 4.84^\#\#^   40.29 ± 4.52^\#\#^   72.01 ± 28.1    
  CL (L/min/kg)         1.56 ± 0.39             2.05 ± 0.72          1.65 ± 0.18          1.46 ± 0.43     
  *V* (L/kg)            397.2 ± 69.9            333.9 ± 135.7        244.5 ± 88.7         434.1 ± 130.5   

Compared with NS, ^\#^*P* \< 0.05 and ^\#\#^*P* \< 0.01.

###### 

Pharmacokinetic parameters of diclofenac in rat plasma ($\overline{x} \pm \text{SD}$, *n* = 6).

  Parameter               NS             ZWD-L          ZWD-M              ZWD-H
  ----------------------- -------------- -------------- ------------------ --------------------
  AUC~0−*t*~ (mg/L·min)   61.96 ± 4.07   56.12±8.19     48.68 ± 13.1^\#^   36.53 ± 5.89^\#\#^
  AUC~0−∞~ (mg/L·min)     67.46 ± 5.36   59.14 ± 8.67   51.11 ± 13.4^\#^   41.01 ± 6.52^\#\#^
  *T* ~1/2~ (min)         35.45 ± 7.81   41.07 ± 26.0   34.99 ± 9.03       52.61 ± 11.5
  CL (L/min/kg)           0.32 ± 0.01    0.34 ± 0.05    0.41 ± 0.10^\#^    0.50 ± 0.09^\#\#^
  *V* (L/kg)              15.58 ± 3.65   19.79 ± 10.6   21.28 ± 8.67       37.38 ± 7.39^\#\#^

Compared with NS, ^\#^*P* \< 0.05 and ^\#\#^*P* \< 0.01.

###### 

Pharmacokinetic parameters of omeprazole in rat plasma ($\overline{x} \pm \text{SD}$, *n* = 6).

  Parameter               NS             ZWD-L               ZWD-M               ZWD-H
  ----------------------- -------------- ------------------- ------------------- -------------------
  AUC~0−*t*~ (mg/L·min)   11.67 ± 1.34   5.86 ± 2.00^\#\#^   5.62 ± 0.97^\#\#^   4.47 ± 0.42^\#\#^
  AUC~0−∞~ (mg/L·min)     12.31 ± 1.59   5.94 ± 1.99^\#\#^   5.85 ± 0.83^\#\#^   4.55 ± 0.38^\#\#^
  *T* ~1/2~ (min)         24.47 ± 8.51   20.55 ± 6.78        25.49 ± 11.1        17.57 ± 4.37
  CL (L/min/kg)           1.65 ± 0.21    3.61 ± 0.87^\#\#^   3.48 ± 0.46^\#\#^   4.43 ± 0.41^\#\#^
  *V* (L/kg)              57.40 ± 19.4   112.4 ± 53.7        132.6 ± 67.2        114.0 ± 39.2

Compared with NS, ^\#^*P* \< 0.05 and ^\#\#^*P* \< 0.01.

###### 

Pharmacokinetic parameters of midazolam in rat plasma ($\overline{x} \pm \text{SD}$, *n* = 6).

  Parameter               NS             ZWD-L              ZWD-M                ZWD-H
  ----------------------- -------------- ------------------ -------------------- --------------------
  AUC~0−*t*~ (mg/L·min)   13.55 ± 2.56   11.57 ± 1.39       10.77 ± 2.98^\#^     9.50 ± 0.96^\#\#^
  AUC~0−∞~ (mg/L·min)     16.08 ± 2.92   12.61 ± 1.30^\#^   11.34 ± 2.95^\#\#^   10.27 ± 1.07^\#\#^
  *T* ~1/2~ (min)         53.32 ± 14.4   38.15 ± 9.11^\#^   31.88 ± 9.42^\#\#^   34.45 ± 5.92^\#\#^
  CL (L/min/kg)           1.28 ± 0.22    1.60 ± 0.17        1.88 ± 0.54^\#^      1.97 ± 0.22^\#\#^
  *V* (L/kg)              97.36 ± 26.3   88.59 ± 24.8       90.43 ± 47.8         97.26 ± 15.5

Compared with NS, ^\#^*P* \< 0.05 and ^\#\#^*P* \< 0.01.

[^1]: Academic Editor: Dr Muhammad Hassham Hassan Bin Asad
